Compare Adaptive Biotechnologies Corp (ADPT) vs Ecopetrol SA (EC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ecopetrol SA — how do they compare? Adaptive Biotechnologies Corp trades at $20.04 (market cap $3.33B), while Ecopetrol SA trades at $15.05 (market cap $28.19B). The key difference: Ecopetrol SA is far larger — about 8.5× Adaptive Biotechnologies Corp's market cap, and Ecopetrol SA pays a 4.42% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EC | |
|---|---|---|
Market Cap | $3.33B | $28.19B |
Sector | Health | Energy |
52-Week High | $22.37 | $16.58 |
52-Week Low | $10.24 | $8.29 |
Enterprise Value | $3.19B | $55.97B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Ecopetrol (EC) trades at $14.69, slightly below the consensus price target of $14.63, with a bearish technical signal and mixed earnings performance. Recent quarters show misses against EPS expectations, while revenue has declined from $159.6T in 2022 to $119.7T in 2025. The company maintains a dividend payout, with a recent H1-26 dividend of $0.66, and holds a BB- credit rating with a stable outlook as affirmed by S&P Global Ratings on June 17, 2026.
The outlook remains cautious due to declining revenue and profitability trends, offset by attractive valuation multiples like a P/E of 10.31. Key risks include operational execution in the energy sector and macroeconomic pressures on oil demand. Analyst sentiment is mixed with a Hold-dominated consensus, suggesting limited near-term upside potential amid ongoing fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
